THC250516C145000
- 7.40
- +0.95+14.73%
Tenet Healthcare Newsroom
Zacks.com Featured Highlights Fox, Universal Technical Institute, Pfizer, Tenet Healthcare and Newmont
US MOVERS&SHAKERS Apr 28-May 02, 2025
Tenet Healthcare: Strong Performance and Growth Potential Justify Buy Rating Despite Lowered Price Target
RBC Capital Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $189
Truist Financial Maintains Tenet Healthcare(THC.US) With Buy Rating, Maintains Target Price $175
UBS Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $230
Tenet Healthcare Is Maintained at Overweight by Barclays
Tenet Healthcare Price Target Raised to $171.00/Share From $161.00 by Barclays
Tenet Healthcare Q1 Results Exceed Expectations Due to Strong Volume, Cost Control, RBC Says
Tenet Healthcare Is Maintained at Buy by UBS
Tenet Healthcare Price Target Raised to $230.00/Share From $217.00 by UBS
Tenet Healthcare Analyst Ratings
A Quick Look at Today's Ratings for Tenet Healthcare(THC.US), With a Forecast Between $165 to $185
Analysts Conflicted on These Healthcare Names: Tenet Healthcare (THC), Incyte (INCY) and Lemaitre Vascular (LMAT)
RBC Raises Price Target on Tenet Healthcare to $189 From $183, Keeps Outperform Rating
Q1 2025 Tenet Healthcare Corp Earnings Call
Express News | Tenet Healthcare Corp : Leerink Partners Cuts Target Price to $170 From $185
Tenet Healthcare's Strong Performance and Strategic Focus Justify Buy Rating
Research Alert: Thc Beats Q1 Eps Estimates As Patient Volumes And Favorable Mix Boost Margins
Tenet Healthcare | 10-Q: Q1 2025 Earnings Report